Dr David Wood will present at the Microbiome Data Congress to discuss the importance of precise gut microbiome profiling for biomarker discovery.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
A/Prof Lutz Krause and Dr David Wood discuss practical applications of metagenomics in microbiome discovery at ASM's Annual Scientific Meeting.
Professor Hugenholtz will discuss approaches to using new tools and data in research and explain the different approaches to taxonomic classification.
A/Prof Krause will discuss the human-first, data-driven approach to therapeutic discovery that Microba employs in their IBD therapeutic program.
Microba launched an IBD Research and Development (R&D) program in 2019 to tackle IBD by mining the gut microbiome for novel biotherapeutics.
Professor Phil Hugenholtz, has been announced as the next Vice President of the International Society for Microbial Ecology (ISME).
Machine learning technology will be used to identify significant associations between microorganisms and genes to predict different disease states.
Microba has backed sufferers of IBD through a donation to support IBD organisation Crohn’s and Colitis Australia.
Microba has received a significant investment from global precision medicine company, Macrogen.